Perceptive Advisors LLC Has $57.52 Million Stock Holdings in Nurix Therapeutics, Inc. $NRIX

Perceptive Advisors LLC increased its position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 4.4% during the 1st quarter, Holdings Channel reports. The fund owned 3,710,877 shares of the company’s stock after buying an additional 155,000 shares during the quarter. Nurix Therapeutics accounts for about 1.1% of Perceptive Advisors LLC’s investment portfolio, making the stock its 24th biggest holding. Perceptive Advisors LLC’s holdings in Nurix Therapeutics were worth $57,519,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Bank of America Corp DE increased its stake in Nurix Therapeutics by 8.9% in the first quarter. Bank of America Corp DE now owns 802,153 shares of the company’s stock valued at $12,433,000 after purchasing an additional 65,595 shares in the last quarter. Stempoint Capital LP bought a new position in shares of Nurix Therapeutics during the first quarter worth $4,886,000. California State Teachers Retirement System boosted its position in shares of Nurix Therapeutics by 45.6% during the first quarter. California State Teachers Retirement System now owns 99,042 shares of the company’s stock worth $1,535,000 after purchasing an additional 31,023 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Nurix Therapeutics by 4.0% during the first quarter. The Manufacturers Life Insurance Company now owns 179,177 shares of the company’s stock worth $2,777,000 after purchasing an additional 6,813 shares in the last quarter. Finally, Quantinno Capital Management LP grew its holdings in shares of Nurix Therapeutics by 32.0% in the 1st quarter. Quantinno Capital Management LP now owns 22,133 shares of the company’s stock valued at $343,000 after buying an additional 5,366 shares during the period.

Insiders Place Their Bets

In other Nurix Therapeutics news, insider Gwenn Hansen sold 5,394 shares of the stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $20.00, for a total transaction of $107,880.00. Following the completion of the transaction, the insider owned 115,005 shares in the company, valued at approximately $2,300,100. This represents a 4.48% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Houte Hans Van sold 14,055 shares of Nurix Therapeutics stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $16.60, for a total value of $233,313.00. Following the completion of the sale, the chief financial officer directly owned 37,592 shares in the company, valued at $624,027.20. This represents a 27.21% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 26,141 shares of company stock valued at $497,652. Company insiders own 6.70% of the company’s stock.

Analysts Set New Price Targets

NRIX has been the subject of a number of recent analyst reports. Morgan Stanley upped their price objective on shares of Nurix Therapeutics from $36.00 to $38.00 and gave the company an “overweight” rating in a research report on Tuesday. Mizuho boosted their target price on Nurix Therapeutics from $30.00 to $34.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Needham & Company LLC reissued a “buy” rating and issued a $34.00 target price on shares of Nurix Therapeutics in a research note on Friday, July 10th. HC Wainwright increased their price target on Nurix Therapeutics from $32.00 to $34.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Finally, BTIG Research reaffirmed a “buy” rating and set a $32.00 price target on shares of Nurix Therapeutics in a research report on Friday, July 10th. Thirteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Nurix Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $34.00.

Nurix Therapeutics Stock Down 1.6%

Nurix Therapeutics stock opened at $23.21 on Friday. The company has a 50 day moving average of $20.54 and a 200-day moving average of $17.85. Nurix Therapeutics, Inc. has a twelve month low of $8.19 and a twelve month high of $25.08. The stock has a market capitalization of $2.41 billion, a PE ratio of -6.73 and a beta of 1.80.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings data on Thursday, July 9th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.08). Nurix Therapeutics had a negative return on equity of 76.09% and a negative net margin of 928.44%.The company had revenue of $9.04 million for the quarter, compared to analyst estimates of $15.29 million. Equities analysts anticipate that Nurix Therapeutics, Inc. will post -2.84 EPS for the current fiscal year.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.